Rationale for combination therapy in myelofibrosis

Best Practice and Research: Clinical Haematology

Volumn 27, Issue 2, 2014, Pages 197-208

  Mascarenhas, John ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Combination therapy; Decitabine; LDE225; Myelofibrosis; Panobinostat; PRM 151; Ruxolitinib

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ALPHA INTERFERON; ANTIFIBROTIC AGENT; DANAZOL; JANUS KINASE; LENALIDOMIDE; PANOBINOSTAT; RUXOLITINIB; SONIDEGIB; STAT PROTEIN; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; BIPHENYL DERIVATIVE; DECITABINE; HOMEODOMAIN PROTEIN; HYDROXAMIC ACID; INDOLE DERIVATIVE; JAK2 PROTEIN, HUMAN; JANUS KINASE 2; PRM-151; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RECOMBINANT PROTEIN; SERUM AMYLOID P;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MYELOFIBROSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; SIGNAL TRANSDUCTION; SURVIVAL; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG EFFECTS; GENE EXPRESSION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PRIMARY MYELOFIBROSIS;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; BIPHENYL COMPOUNDS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GENE EXPRESSION; HEMATOPOIETIC STEM CELLS; HOMEODOMAIN PROTEINS; HUMANS; HYDROXAMIC ACIDS; INDOLES; JANUS KINASE 2; MUTATION; PRIMARY MYELOFIBROSIS; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECOMBINANT PROTEINS; SERUM AMYLOID P-COMPONENT;

EID: 84906938292     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2014.07.009     Document Type: Review

References (70)

1. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: A study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) . Blood 2010 Mar 4; 115 (9) : 1703-8.
2. Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: Therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010 Apr 15; 115 (15) : 3109-17.
3. Tefferi A, Vaidya R, Caramazza D, et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: A comprehensive cytokine profiling study. J Clin Oncol Off J Am Soc Clin Oncol 2011 Apr 1; 29 (10) : 1356-63.
4. Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012 Mar 1; 366 (9) : 787-98.
5. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012 Mar 1; 366 (9) : 799-807.
6. Pardanani A, Laborde RR, Lasho TL, et al. Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia 2013 Jun; 27 (6) : 1322-7.
7. Mascarenhas J, Lu M, Li T, et al. A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF) . Br J Haematol 2013 Apr; 161 (1) : 68-75.
8. Tefferi A, Begna K, Laborde RR, et al. Imetelstat, a telomerase inhibitor, induces morphologic and molecular remissions in myelofibrosis and reversal of bone marrow fibrosis. In: ASH Annual Meeting Abstracts, vol. 122 (21) ; 2013.
9. Kroger N, Badbaran A, Holler E, et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative realtime PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007 Feb 1; 109 (3) : 1316-21.
10. Stubig T, Alchalby H, Ditschkowski M, et al. JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post ET/PV myelofibrosis. Leukemia 2014 Feb 26 [Epub ahead of print].
11. Jaekel N, Behre G, Behning A, et al. Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib. Bone Marrow Transplant 2014 Feb; 49 (2) : 179-84.
12. Robin M, Tabrizi R, Mohty M, et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: A report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC) . Br J Haematol 2011 Feb; 152 (3) : 331-9.
13. Ciurea SO, Sadegi B, Wilbur A, et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol 2008 Apr; 141 (1) : 80-3.
14. Alchalby H, Yunus DR, Zabelina T, et al. Risk models predicting survival after reduced-intensity transplantation for myelofibrosis. Br J Haematol 2012 Apr; 157 (1) : 75-85.
15. Ferrara JL, Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006 Jan; 43 (1) : 3-10.
16. Glaser KB. HDAC inhibitors: Clinical update and mechanism-based potential. Biochem Pharmacol 2007 Sep 1; 74 (5) : 659-71.
17. Wang Y, Fiskus W, Chong DG, et al. Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells. Blood 2009 Dec 3; 114 (24) : 5024-33.
18. Tefferi A, Barosi G, Mesa RA, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for myelofibrosis research and treatment (IWG-MRT) . Blood 2006 Sep 1; 108 (5) : 1497-503.
19. DeAngelo DJ, Mesa RA, Fiskus W, et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol 2013 Aug; 162 (3) : 326-35.
20. Evrot E, Ebel N, Romanet V, et al. JAK1/2 and pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease. Clin Cancer Res Off J Am Assoc Cancer Res 2013 Nov 15; 19 (22) : 6230-41.
21. Ribrag V, Harrison C, Heidel F, et al. A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with primary myelofibrosis (PMF) , Postepolycythemia vera MF (PPV-MF) , or posteessential thrombocythemia MF (PET-MF) : Identification of the recommended phase 2 dose. In: ASH Annual Meeting Abstracts, vol. 122 (21) ; 2013. p. 4045.
22. Rosti V, Massa M, Vannucchi AM, et al. The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia. Blood Cells Mol Dis 2007 May-Jun; 38 (3) : 280-6.
23. Wang X, Zhang W, Ishii T, et al. Correction of the abnormal trafficking of primary myelofibrosis CD34+ cells by treatment with chromatin-modifying agents. Cancer Res 2009 Oct 1; 69 (19) : 7612-8.
24. Wang JC, Chen W, Nallusamy S, et al. Hypermethylation of the P15INK4b and P16INK4a in agnogenic myeloid metaplasia (AMM) and AMM in leukaemic transformation. Br J Haematol 2002 Mar; 116 (3) : 582-6.
25. Jones LC, Tefferi A, Idos GE, et al. RARbeta2 is a candidate tumor suppressor gene in myelofibrosis with myeloid metaplasia. Oncogene 2004 Oct 14; 23 (47) : 7846-53.
26. Bogani C, Ponziani V, Guglielmelli P, et al. Hypermethylation of CXCR4 promoter in CD34+ cells from patients with primary myelofibrosis. Stem Cells 2008 Aug; 26 (8) : 1920-30.
27. Teofili L, Martini M, Cenci T, et al. Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int J Cancer 2008 Oct 1; 123 (7) : 1586-92.
28. Danilov AV, Relias V, Feeney DM, et al. Decitabine is an effective treatment of idiopathic myelofibrosis. Br J Haematol 2009 Apr; 145 (1) : 131-2.
29. Mascarenhas J, Navada S, Malone A, et al. Therapeutic options for patients with myelofibrosis in blast phase. Leuk Res 2010 Sep; 34 (9) : 1246-9.
30. Liu Y, Tabarroki A, Billings S, et al. Successful use of very low dose subcutaneous decitabine to treat high-risk myelofibrosis with sweet syndrome that was refractory to 5-azacitidine. Leuk Lymphoma 2014 Feb; 55 (2) : 447-9.
31. Odenike OM, Godwin JE, Van Besien K, et al. Phase II trial of low dose, subcutaneous decitabine in myelofibrosis. In: ASH Annual Meeting Abstracts, vol. 112 (11) ; November 16, 2008. p. 2809.
32. Tam CS, Nussenzveig RM, Popat U, et al. The natural history and treatment outcome of blast phase BCR-ABLmyeloproliferative neoplasms. Blood 2008 Sep 1; 112 (5) : 1628-37.
33. Mesa RA, Li CY, Ketterling RP, et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with 91 cases. Blood 2005 Feb 1; 105 (3) : 973-7.
34. Thepot S, Itzykson R, Seegers V, et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: A report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM) . Blood 2010 Nov 11; 116 (19) : 3735-42.
35. Quintas-Cardama A, Tong W, Kantarjian H, et al. A phase II study of 5-azacitidine for patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. Leukemia 2008 May; 22 (5) : 965-70.
36. Mesa RA, Verstovsek S, Rivera C, et al. 5-Azacitidine has limited therapeutic activity in myelofibrosis. Leukemia 2009 Jan; 23 (1) : 180-2.
37. Eghtedar A, Verstovsek S, Estrov Z, et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012 May 17; 119 (20) : 4614-8.
38. Rampal R, Mascarenhas J. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm. Curr Opin Hematol 2014 Mar; 21 (2) : 65-71.
39. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012 Mar 22; 366 (12) : 1079-89.
40. Mascarenhas J, Heaney ML, Najfeld V, et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP) : Formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res 2012 Dec; 36 (12) : 1500-4.
41. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008 Sep 15; 112 (6) : 2190-8.
42. Fiskus W, Verstovsek S, Manshouri T, et al. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells. Mol Cancer Ther 2013 May; 12 (5) : 577-88.
43. Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood 2012 Mar 8; 119 (10) : 2196-204.
44. Zhao C, Chen A, Jamieson CH, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009 Apr 9; 458 (7239) : 776-9.
45. Bhagwat N, Keller M, Rampal R, et al. Improved efficacy of combination of JAK2 and hedgehog inhibitors in myelofibrosis. In: ASH Annual Meeting Abstracts; 2013.
46. Rodon J, Tawbi HA, Thomas AL, et al. A phase 1, multicenter, open-label, first-in-human, dose-escalation study of the oral hedgehog inhibitor sonidegib (LDE225) in patients with advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res 2014 Feb 12 [Epub ahead of print].
47. Saci A, Pinzon-Ortiz M, Wang D, et al. The combination of JAK inhibitor, ruxolitinib, and PIM inhibitor, LGH447, in preclinical models of myeloproliferative neoplasia. In: ASH Annual Meeting Abstracts, vol. 122 (21) ; 2013.
48. Bartalucci N, Bogani C, Martinelli S, et al. The PI3K specific inhibitor BKM120 results effective and synergizes with ruxolitinib in preclinical models of myeloproliferative neoplasms. In: ASH Annual Meeting Abstracts, vol. 122 (21) ; 2012.
49. Arenas A, Hernandez-Camp P, Primo D, et al. High throughput screening, with a flow cytometry automated platform (ex vivo biotech) , to identify potential combination partners, for the JAK 2 inhibitor ruxolitinib. In: ASH Annual Meeting Abstracts, vol. 122 (21) ; 2013.
50. McMullin MF, Harrison CN, Niederwieser D, et al. The use of erythropoietic-stimulating agents (ESAs) with ruxolitinib in patients with primary myelofibrosis (PMF) , post-polycythemia vera myelofibrosis (PPV-MF) , and post-essential thrombocythemia myelofibrosis (PET-MF) . In: ASH Annual Meeting Abstracts, vol. 120 (21) ; November 16, 2012. p. 2838.
51. Brubaker LH, Briere J, Laszlo J, et al. Treatment of anemia in myeloproliferative disorders: A randomized study of fluoxymesterone v transfusions only. Arch Intern Med 1982 Aug; 142 (8) : 1533-7.
52. Besa EC, Nowell PC, Geller NL, et al. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: The value of chromosomal studies in predicting response and survival. Cancer 1982 Jan 15; 49 (2) : 308-13.
53. Cervantes F, Hernandez-Boluda JC, Alvarez A, et al. Danazol treatment of idiopathic myelofibrosis with severe anemia. Haematologica 2000 Jun; 85 (6) : 595-9.
54. Stadtmauer EA, Cassileth PA, Edelstein M, et al. Danazol treatment of myelodysplastic syndromes. Br J Haematol 1991 Apr; 77 (4) : 502-8.
55. Cervantes F, Alvarez-Larran A, Domingo A, et al. Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: Long-term results in 30 patients. Br J Haematol 2005 Jun; 129 (6) : 771-5.
56. Tabarroki A, Tiu RV. Immunomodulatory agents in myelofibrosis. Expert Opin Investig Drugs 2012 Aug; 21 (8) : 1141-54.
57. Tefferi A, Passamonti F, Barbui T, et al. Phase 3 study of pomalidomide in myeloproliferative neoplasm (MPN)-Associated myelofibrosis with RBC-transfusion-dependence. In: ASH Annual Meeting Abstractsvol. 122 (21) ; 2013.
58. Begna KH, Mesa RA, Pardanani A, et al. A phase-2 trial of low-dose pomalidomide in myelofibrosis. Leukemia 2011 Feb; 25 (2) : 301-4.
59. Cervantes F, Alvarez-Larran A, Hernandez-Boluda JC, et al. Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: Results in 20 patients and review of the literature. Br J Haematol 2004 Nov; 127 (4) : 399-403.
60. Tsiara SN, Chaidos A, Bourantas LK, et al. Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis. Acta Haematol 2007; 117 (3) : 156-61.
61. Huang J, Tefferi A. Erythropoiesis stimulating agents have limited therapeutic activity in transfusion-dependent patients with primary myelofibrosis regardless of serum erythropoietin level. Eur J Haematol 2009 Aug; 83 (2) : 154-5.
62. Huang J, Li CY, Mesa RA, et al. Risk factors for leukemic transformation in patients with primary myelofibrosis. Cancer 2008 Jun 15; 112 (12) : 2726-32.
63. Thiele J, Kvasnicka HM. Grade of bone marrow fibrosis is associated with relevant hematological findings-A clinicopathological study on 865 patients with chronic idiopathic myelofibrosis. Ann Hematol 2006 Apr; 85 (4) : 226-32.
64. Gianelli U, Vener C, Bossi A, et al. The European consensus on grading of bone marrow fibrosis allows a better prognostication of patients with primary myelofibrosis. Mod Pathol Off J U S Can Acad Pathol Inc 2012 Sep; 25 (9) : 1193-202.
65. Duffield JS, Lupher Jr. ML. PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis. Drug News Perspect 2010 Jun; 23 (5) : 305-15.
66. Murray LA, Rosada R, Moreira AP, et al. Serum amyloid P therapeutically attenuates murine bleomycin-induced pulmonary fibrosis via its effects on macrophages. PloS One 2010; 5 (3) : E9683.
67. Murray LA, Kramer MS, Hesson DP, et al. Serum amyloid P ameliorates radiation-induced oral mucositis and fibrosis. Fibrogenesis Tissue Repair 2010; 3: 11.
68. Murray LA, Chen Q, Kramer MS, et al. TGF-beta driven lung fibrosis is macrophage dependent and blocked by serum amyloid P. Int J Biochem Cell Biol 2011 Jan; 43 (1) : 154-62.
69. Hasselbalch HC. A new era for IFN-alpha in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms. Expert Rev Hematol 2011 Dec; 4 (6) : 637-55.
70. Hasselbalch HC. The role of cytokines in the initiation and progression of myelofibrosis. Cytokine Growth Factor Rev 2013 Apr; 24 (2) : 133-45.